Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Notes Payables (2020 - 2025)

SAB Biotherapeutics' Notes Payables history spans 6 years, with the latest figure at $138554.0 for Q1 2025.

  • For Q1 2025, Notes Payables fell 83.42% year-over-year to $138554.0; the TTM value through Mar 2025 reached $138554.0, down 83.42%, while the annual FY2024 figure was $275849.0, 73.75% down from the prior year.
  • Notes Payables reached $138554.0 in Q1 2025 per SABSW's latest filing, down from $275849.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.8 million in Q4 2021 to a low of $25013.0 in Q3 2022.
  • Average Notes Payables over 5 years is $609781.8, with a median of $541644.0 recorded in 2023.
  • Peak YoY movement for Notes Payables: soared 2065.45% in 2023, then crashed 83.42% in 2025.
  • A 5-year view of Notes Payables shows it stood at $1.8 million in 2021, then crashed by 57.0% to $772665.0 in 2022, then soared by 36.0% to $1.1 million in 2023, then plummeted by 73.75% to $275849.0 in 2024, then crashed by 49.77% to $138554.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Notes Payables are $138554.0 (Q1 2025), $275849.0 (Q4 2024), and $615818.0 (Q2 2024).